Viatris Upgraded to Strong Buy on Pipeline Growth and Cash Generation
Mare Evidence Lab has upgraded Viatris (NASDAQ: VTRS) to a Strong Buy rating, shifting the investment thesis from a cost-cutting narrative to a pipeline-driven growth story. The upgrade is supported by robust pipeline catalysts and a credible long-term growth framework. Viatris targets a five-year sales compound annual growth rate midpoint of 3.5%, which exceeds current consensus estimates. This growth is expected to be driven by $450–550 million in annual contributions from new products and upside potential from branded assets. Key pharmaceutical assets, including Selatogrel and Cenerimod, along with upcoming launches such as meloxicam, are projected to support growth reacceleration and margin expansion. Furthermore, management forecasts approximately $11 billion in cash generation through 2030. This strong cash flow will facilitate disciplined capital allocation, selective mergers and acquisitions, and a strategic shift toward higher-value generics. The analysts maintain a positive outlook on the company's ability to deliver value through these strategic initiatives and financial strengths.
Wire timeline
Viatris Upgraded to Strong Buy on Pipeline Growth and Cash Generation
Mare Evidence Lab has upgraded Viatris (NASDAQ: VTRS) to a Strong Buy rating, shifting the investment thesis from a cost-cutting narrative to a pipeline-driven growth story. The upgrade is supported by robust pipeline catalysts and a credible long-term growth framework. Viatris targets a five-year sales compound annual growth rate midpoint of 3.5%, which exceeds current consensus estimates. This growth is expected to be driven by $450–550 million in annual contributions from new products and upside potential from branded assets. Key pharmaceutical assets, including Selatogrel and Cenerimod, along with upcoming launches such as meloxicam, are projected to support growth reacceleration and margin expansion. Furthermore, management forecasts approximately $11 billion in cash generation through 2030. This strong cash flow will facilitate disciplined capital allocation, selective mergers and acquisitions, and a strategic shift toward higher-value generics. The analysts maintain a positive outlook on the company's ability to deliver value through these strategic initiatives and financial strengths.
All Articles on Seeking Alpha